Navigation Links
ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
Date:12/17/2009

logy and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2008 and Anadys' Form 10-Q for the quarter ended September 30, 2009. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Pegasys® and Copegus® are registered trademarks of Hoffman-La Roche Inc.

SOURCE Anadys Pharmaceuticals, Inc.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
11. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... March 2, 2015 Valencia Technologies Corporation (" ... patient with its radically small device for the treatment ... results in this randomized, double-blinded, controlled trial are compelling ... confidence that it will succeed in a large U.S. ... clinical results, Valencia has successfully ...
(Date:3/2/2015)... Following announcements from both Novartis and ... Inc. (NASDAQ:  ARRY) today announced the completion of ... Novartis.  Along with global ownership of both assets, ... million from Novartis. Ron Squarer, Chief ... the Novartis-GSK transaction, Array now owns both binimetinib ...
(Date:3/2/2015)... , March 2, 2015  Galmed Pharmaceuticals Ltd. ... company focused on the development and commercialization of a ... and cholesterol gallstones, today announced that Josh Blacher ... at the 27th Annual ROTH conference in ... 2015 at 2:30 PM Pacific Standard Time. A live ...
Breaking Medicine Technology:Valencia Technologies Implants its 48th Patient, Continues Equity Crowdfunding 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 3Array Announces Completion Of Binimetinib And Encorafenib Transactions 4Array Announces Completion Of Binimetinib And Encorafenib Transactions 5Galmed Pharmaceuticals to Present at the 27th Annual ROTH Conference 2
(Date:3/2/2015)... New York (PRWEB) March 02, 2015 ... Recovery at Recovery Unplugged™—will be delivering a plenary ... Singer/Songwriter's Perspective on the Art of Healing and ... Disorders (NCAD) and Behavioral Healthcare Executive Summit (BHES).     ... name, Mr. Supa’s songs have been recorded by ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 The ... grow at a CAGR of 6.1% to reach ... 2014. , Factors such as advantages of ... healthcare costs owing to minimally invasive surgeries and ... population are driving the global minimally invasive surgical ...
(Date:3/2/2015)... DC (PRWEB) March 02, 2015 Atlantic ... publication of AIS’s Directory of Health Plans: 2015 ... resource available on the U.S. health plan market, with ... in the United States. , Available as a ... Summary” of enrollment trends in quick-view tables and charts, ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 In light ... of anticoagulant Xarelto (rivaroxaban) tablets, Ford & ... may be helpful for future users, but may come ... injuries from taking the drug. The FDA has now ... under Adverse Reactions on Xarelto's label. The term “cytolytic ...
(Date:3/2/2015)... ProvidaStaff has announced today that it is changing ... EDU Healthcare to reflect better on the commitment ... nationwide. , “ProvidaStaff has always been a leading healthcare ... Angela M. Lewis, President of ProvidaStaff. “We continue to ... of EDU Healthcare better aligns our services to our ...
Breaking Medicine News(10 mins):Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 4Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3
... finds , WEDNESDAY, Feb. 17 (HealthDay News) -- Good ... improve their odds of staying healthy: baked rhubarb may ... garden rhubarb for 20 minutes dramatically boosted levels of ... polyphenols selectively kill or prevent the growth of cancer ...
... Rural areas tend to fare worse than urban locales, ... -- Want to know how healthy your county is? ... ranking of nearly every county in the nation shows ... on where they live. , Researchers from University of ...
... , GREENBRAE, Calif. , Feb. 17 ... of transformational media, announced today the release of Sound Sanctuaries ... Malkin . , Designed to help listeners experience deep inner peace ... moving music by Malkin that he says will "awaken the spirit ...
... N.C. , Feb. 17 MedCath Corporation (Nasdaq: ... they have entered into a definitive agreement to sell substantially ... David,s Healthcare Partnership, L.P. ("St. David,s"). The transaction is expected ... to customary closing conditions and regulatory requirements. , The sale ...
... , ... Services marked the start of 2010 with the official launch of a new state-of-the-art ... industries, this latest addition to the Almac services portfolio is set to revolutionise the ... ...
... MyNursingUniforms ... nursing uniform store. , ... February 17, 2010 -- MyNursingUniforms (MNU), a leader in online retail for nursing uniforms and ... , ,MNU made the expansion to their online store in both the shoe and medical ...
Cached Medicine News:Health News:County-By-County Report Sizes Up Americans' Health 2Health News:County-By-County Report Sizes Up Americans' Health 3Health News:New CD Collections Promise to Create a Sound Sanctuary in Your Home, Office, or Car 2Health News:MedCath Enters Definitive Agreement To Sell Heart Hospital of Austin 2Health News:Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials 2Health News:Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials 3Health News:MyNursingUniforms Adds Skechers Brand Name Shoes and Scrubs to Store 2
... The electronic, motorized ... for all applications of ... and hard specimens in ... labs. These instruments display ...
... Leica RM2255 rotary microtome, designed for ... and resin-embedded specimens, offers a broad ... research histology laboratory. This microtome meets ... a compact, fully motorized/electronic microtome for ...
State-of-the-Art modular embedding station providing performance and ease of use to meet the needs of the most demanding user....
... system for specimen surface preparation is the ... attachment Leica SP2600. ,Ultramilling is often a ... microtomy in sample preparation. Especially with difficult ... located side by side in one specimen ...
Medicine Products: